[A20-24] Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V

Last updated 15.06.2020

Project no.:
A20-24

Commission:
Commission awarded on 11.03.2020 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Muscles, bones and joints

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

15.06.2020

Romosozumab in osteoporosis: considerable added benefit for women after menopause

Fewer vertebral fractures and fewer other typical fractures in postmenopausal women with severe osteoporosis at high risk of fracture

Project no. Title Status
A20-67 Romosozumab (osteoporosis) - Addendum to Commission A20-24 Commission completed

Federal Joint Committee (G-BA)

2020-09-03 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.